Mark Gergen

Mark Gergen

Nessuna posizione attualmente
63 anni
Health Technology
Commercial Services
Consumer Services

Profilo

Mark J.
Gergen
is an Independent Director at Aristea Therapeutics, Inc. He previously served as the Executive Chairman at Poseida Therapeutics, Inc. from 2024 to 2025.
Mark also held positions as a Director at Aperio Technologies, Inc., Chief Financial & Development Officer at Advanced Tissue Sciences, Inc. from 1999 to 2003, and Senior Vice President-Corporate Development at Amylin Pharmaceuticals, Inc. from 2005 to 2012.
He was also a Principal at Jostens, Inc. and Medtronic, Inc. Mark served as the Chief Operating Officer & Senior Vice President at Halozyme Therapeutics, Inc. from 2016 to 2017, and as the Executive Vice President at CardioNet LLC from 2003 to 2005.
He was also a Principal at Premier Healthcare Solutions, Inc. and served as the Chief Operating Officer, Secretary & Executive VP at Mirati Therapeutics, Inc. in 2016.
Mr. Gergen obtained his undergraduate degree from Minot State University and his graduate degree from The University of Minnesota Law School.

Precedenti posizioni note di Mark Gergen

SocietàPosizioneFine
POSEIDA THERAPEUTICS, INC. Amministratore Delegato 01/01/2024
HALOZYME THERAPEUTICS, INC. Direttore operativo 29/09/2017
MIRATI THERAPEUTICS Direttore operativo 16/09/2016
Corporate Officer/Principal 01/11/2012
Corporate Officer/Principal 01/03/2005
Vedi nel dettaglio l'esperienza di Mark Gergen

Formazione di Mark Gergen

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

61

Relazioni di 1° grado

13

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private13

Commercial Services

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

  1. Mercati
  2. Insiders
  3. Mark Gergen